NCT00790127View on ClinicalTrials.gov

Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Beta Thalassemia
Interventions
DRUG

HQK-1001

HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days

DRUG

Placebo

Matching placebo capsules administered once a day, orally, for 56 days

Trial Locations (2)

10700

Siriraj Hospital, Bangkok

Unknown

Chronic Care Center, Beirut

Sponsors
All Listed Sponsors
lead

HemaQuest Pharmaceuticals Inc.

INDUSTRY